The invention relates to preparation comprising at least one probiotic strain belonging to the genus Bacillus megaterium, and a polyunsaturated fatty acid component comprising at least one omega-3 or omega-6 fatty acid selected from eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), arachidonic acid (ARA), alpha linolenic acid, stearidonic acid, eicosatetraenoic acid, docosapentaenoic acid, linoleic acid, γ-linolenic acid, wherein the polyunsaturated fatty acid component comprises an omega-3 or omega-6 fatty acid salt. The invention further relates to use of the inventive preparation as a feed or food supplement, pharmaceutical product, feed-or foodstuff compositions and for topical applications.

The present disclosure provides a nutritional formula comprising alpha-lactalbumin enriched whey protein concentrate; lactoferrin; oleic acid-palmitic acid-oleic acid triglyceride; lactose; lutein; docosahexanoic acid; arachidonic acid; galactooligosaccharides; and fructooligosaccharides. The provided nutritional formulas may be useful in providing nutrition and/or promoting postnatal development of a subject (e.g., promoting postnatal development of an infant's gastrointestinal tract, promoting proper gastrointestinal function, nutrient absorption, proper immune system development, etc.). Also provided are powder forms, reconstituted formulas, kits, methods, and uses that include or involve a nutritional formula described herein.

The present disclosure provides a nutritional formula comprising alpha-lactalbumin enriched whey protein concentrate; lactoferrin; oleic acid-palmitic acid-oleic acid triglyceride; lactose; lutein; docosahexanoic acid; arachidonic acid; galactooligosaccharides; and fructooligosaccharides. The provided nutritional formulas may be useful in providing nutrition and/or promoting postnatal development of a subject (e.g., promoting postnatal development of an infant's gastrointestinal tract, promoting proper gastrointestinal function, nutrient absorption, proper immune system development, etc.). Also provided are powder forms, reconstituted formulas, kits, methods, and uses that include or involve a nutritional formula described herein.

The present invention relates to a pharmaceutical composition comprising a mixture extract of Coptis Rhizome and Schizonepeta tenuifolia as an active ingredient for prevention or treatment of an inflammatory bowel disease. The use of Coptis Rhizome and Schizonepeta tenuifolia extracts of the present invention can provide a pharmaceutical composition for prevention or treatment of an inflammatory bowel disease, the pharmaceutical composition being capable of being used safely on the human body without toxicity and side effects, or can provide a food composition and a feed composition each for prevention or alleviation of an inflammatory bowel disease.

The present invention relates to a pharmaceutical composition comprising a mixture extract of Coptis Rhizome and Schizonepeta tenuifolia as an active ingredient for prevention or treatment of an inflammatory bowel disease. The use of Coptis Rhizome and Schizonepeta tenuifolia extracts of the present invention can provide a pharmaceutical composition for prevention or treatment of an inflammatory bowel disease, the pharmaceutical composition being capable of being used safely on the human body without toxicity and side effects, or can provide a food composition and a feed composition each for prevention or alleviation of an inflammatory bowel disease.

Novel polypeptides of fungal origin with catalase active are active, gastric stable and thermal stable, and effective for use in animal feed additives. The use of fungal catalases in animal feed improve animal growth, animal health and intestinal health of animals

Novel polypeptides of fungal origin with catalase active are active, gastric stable and thermal stable, and effective for use in animal feed additives. The use of fungal catalases in animal feed improve animal growth, animal health and intestinal health of animals

The present invention relates to a composition containing Dolichos lablab Linn. extract as an active ingredient for easing hangovers, and preventing, alleviating or treating alcoholic gastrointestinal diseases, the composition having an effect in restoring gastrointestinal wall damaged by alcohol consumption, and being capable of reducing alcohol and acetaldehyde content in the blood as well as increasing aldehyde dehydrogenase activity therein. Therefore, the Dolichos lablab Linn. extract according to the present invention can be used for easing hangovers, and as healthy functional food or medicine that can prevent, alleviate or treat alcoholic gastrointestinal diseases.

The present disclosure provides methods and formulations for reducing ammonia and carbon dioxide emissions from a bovine using lubabegron, or a physiologically acceptable salt thereof. The present disclosure also provides bovine feed additives and bovine feed compositions.

The present disclosure provides methods and formulations for reducing ammonia and carbon dioxide emissions from a bovine using lubabegron, or a physiologically acceptable salt thereof. The present disclosure also provides bovine feed additives and bovine feed compositions.